<DOC>
	<DOCNO>NCT03034044</DOCNO>
	<brief_summary>This study aim observe safety efficacy Xyntha Solofuse prefilled syringe set routine practice . The primary objective detect medically significant event ( factor VIII inhibitor ) . The secondary objective observe overall efficacy safety Xyntha Solofuse prefilled syringe include serious adverse event . In open-label , non-comparative , observational , non-interventional , retrospective multi-center study , post-marketing surveillance data collect retrospectively 6 month initial administration day Xyntha Solofuse prefilled syringe injected patient administer Xyntha Solofuse prefilled syringe . As specified product approval issue Ministry Food Drug Safety , study conduct 4 year approval date . At least 600 study subject enrol study meet MFDS requirement . Although 600 assign number study subject , number case adjust consider actual number enrol subject study start day .</brief_summary>
	<brief_title>Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>. Inclusion criterion To eligible enroll study , study subject meet follow inclusion criterion : 1 . Hemophilia A ( congenital factor VIII deficiency ) patient administer accord indication product 1 ) Control prevention bleed episode routine surgical prophylaxis patient hemophilia A ( congenital factor VIII deficiency ) 2 ) This drug contain von Willebrand factor , therefore , indicate von Willebrand 's disease 2 . Those administered Xyntha Solofuse prefilled syringe least Exclusion criterion Patients satisfy follow criterion include study accord local labeling : 1 . Patients history hypersensitivity Xyntha Solofuse prefilled syringe ingredient drug . 2 . Patients history hypersensitivity hamster protein . 3 . Patients bleed disorder hemophilia A . 4 . Patients history FVIII inhibitor , currently suspect FVIII inhibitor . In case inhibitor titer quantify Bethesda Units laboratory test result within normal laboratory range least 0.6 BU/mL . If laboratory test perform , investigator determine whether inhibitor exist base clinical assessment result show decrease efficacy replacement FVIII ( e.g . bleed least , replacement antibleeding agent need administer , frequency dosage replacement FVIII therapy need increase ) . 5 . Use immunomodulatory therapy . ( e.g . intravenous injection immunoglobulin , use regular systemic corticosteroid , cyclosporine , mediator antiTNFÎ± )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>